ACS Medicinal Chemistry Letters

PATENT HIGHLIGHT

pubs.acs.org/acsmedchemlett

Triazine Analogues as NS5B Inhibitors for the Treatment of HCV

Jean-Francois Brazeau[†] and Gerard Rosse*[,†,‡]

[†]Structure Guided Chemistry, Dart Neuroscience LLC, 7473 Lusk Boulevard, San Diego, California 92121, United States

[‡]Adjunct Associate Professor, Department of Pharmacology and Physiology, College of Medicine, Drexel University, New College Building, 245 North 15th Street, Philadelphia, Pennsylvania 19102, United States

Title:	Triazine Analogues as NS5B Inhibitors for the Treatment of HCV		
Patent/Patent Application Number:	US 2013/0203758 A1	**Publication date:**	August 8, 2013
Priority Application:	US 2012/61595239	**Priority date:**	February 6, 2012
Inventors:	Wang, T.; Scola, P. M.; Zhang, Z.; Yin, Z.; Zhao, Q.		
Assignee Company:	Bristol-Myers Squibb		
Disease Area:	HCV	**Biological Target:**	NS5B
Summary:	The present application claims a series of triazine analogues that demonstrate activity against hepatitus C virus NS5B protein.		

Important Compound Classes:



Key Structures:



Compound 1006



Compound 3577

Biological Assay: Compound efficacy was evaluated using HCV replicon luciferase assay.

Special Issue: HCV Therapies

Received: January 31, 2014
Published: February 12, 2014

Pharmacological Data:

	HCV replicon assay (EC_{50}, nM)
Compound **1006**	0.69
Compound **3577**	0.16

Synthesis: >50 compounds were synthesized.

AUTHOR INFORMATION

Corresponding Author
*E-mail: grosse@dartneuroscience.com.

Notes
The authors declare no competing financial interest.